Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on BioCryst Pharma (NASDAQ:BCRX) and maintained a $12 price target for the company's stock.
January 08, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on BioCryst Pharma and maintained a $12 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $12 price target by a reputable analyst like Serge Belanger could lead to increased investor confidence in BioCryst Pharma. This endorsement may result in a positive short term impact on the stock price as it suggests the analyst sees potential for the stock to grow to or beyond the target price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100